Mercado Global da Psoríase – Tendências do Setor e Previsão para 2029

Análise e dimensão do mercado

Nos últimos anos, prevê-se que o mercado da psoríase prolifere durante o período de previsão. Apesar de os cuidados de saúde estarem a migrar progressivamente para cuidados baseados no valor, de forma a obter melhores resultados para os doentes e melhorar a qualidade de vida, o aumento global da prevalência da psoríase está a encorajar investimentos em estratégias de tratamento e gestão. Como resultado, os fabricantes da indústria da psoríase mudaram o seu foco para a investigação e desenvolvimento, a fim de melhorar a gestão da doença, resultando na criação de medicamentos mais recentes e mais eficazes.

A Data Bridge Market Research analisa que o mercado da psoríase foi avaliado em 24,33 mil milhões de dólares em 2021 e deverá atingir os 49,20 mil milhões de dólares até 2029, registando um CAGR de 9,20% durante o período de previsão de 2022 a 2029. O relatório de mercado com curadoria da Data A equipa da Bridge Market Research inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Definição de mercado

A psoríase é uma doença da pele em que as células da pele se reproduzem 10 vezes mais rapidamente do que deveriam. Isto provoca a formação de manchas vermelhas ásperas com escamas brancas na pele. Podem crescer no couro cabeludo, cotovelos, joelhos e zona lombar, mas são mais comuns aí. É impossível transmitir a psoríase de uma pessoa para outra. O início da idade adulta é quando a psoríase surge pela primeira vez. Afeta apenas alguns locais para a maioria das pessoas. A psoríase pode espalhar-se por todo o corpo em situações extremas.

Âmbito do relatório e segmentação de mercado

Psoriasis Market Dynamics

Drivers

• Rise in the prevalence of psoriasis

The rising prevalence of psoriasis is a major factor driving the psoriasis market's growth rate. Although the actual cause of psoriasis is unknown, some genetic and environmental factors may contribute to the disease's onset. The majority of current therapies try to slow disease progression by preventing keratinocyte hyperproliferation.  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of psoriasis market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the psoriasis market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of psoriasis market. Along with this, rising geriatric population and surge in biological therapy approval will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the psoriasis market growth. The rising number of psoriasis cases worldwide has prompted manufacturing companies to embark on research and development initiatives to develop new psoriasis treatment alternatives.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the psoriasis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the medication will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about psoriasis  and its associated complications will pose major challenges to the market's growth rate. Additionally, the dearth of favourable reimbursement policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This psoriasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psoriasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Psoriasis is becoming more common all over the world. According to the World Psoriasis Day consortium, 125 million individuals suffer from psoriasis each year, accounting for 2 to 3% of the global population.

Psoriasis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Psoriasis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of psoriasis in recent months.

Recent Development

• In January 2022, The US Food and Drug Administration (FDA) had approved AbbVie's SKYRIZI (risankizumab-rzaa) for the treatment of individuals with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and affects around 30% of psoriasis patients.

Global Psoriasis Market Scope

The psoriasis market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Nail Psoriasis
• Guttate Psoriasis
• Psoriatic Arthritis
• Others

Treatment

• Medication

Tumour necrosis factor inhibitors

Interleukin-inhibitors

Vitamin D analogues

Corticosteroids

Others

• Phototherapy
• Others

Diagnosis

• Physical Examination
• Skin Biopsy
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Psoriasis Market Regional Analysis/Insights

The psoriasis market is analysed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the psoriasis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the psoriasis market because of the growing presence of major key players and the rising number of research and development activities will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to the surging number of generic manufacturers and growing government initiatives in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado da psoríase

O cenário competitivo do mercado da psoríase fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da psoríase.

Alguns dos principais players que operam no mercado da psoríase são:

• (EUA)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suíça)
• Mylan NV (EUA)
• (Israel)
• Sanofi (França)
• Boehringer Ingelheim International GmbH. (Alemanha)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (EUA)
• Bayer AG (Alemanha)
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd. (Suíça)
• Empresa Bristol-Myers Squibb (EUA)
• Cadila Pharmaceuticals (Índia) 
• Eli Lilly and Company (EUA)
• LEO Pharma A/S (Dinamarca)
• (EUA)
• Aurobindo Pharma (Índia)
• Lupin (Índia)
• Corporação Sumitomo (Japão)

SKU-53466